1. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo.
- Author
-
Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, Kam TT, Gu H, Sit KY, Hsin MKY, Au TWK, Poon LLM, Peiris M, Nicholls JM, and Chan MCW
- Subjects
- Angiotensin-Converting Enzyme 2 metabolism, Animals, COVID-19 epidemiology, COVID-19 transmission, COVID-19 virology, Cathepsins metabolism, Chlorocebus aethiops, Endocytosis, Humans, In Vitro Techniques, SARS-CoV-2 immunology, Serine Endopeptidases genetics, Serine Endopeptidases metabolism, Tissue Culture Techniques, Vero Cells, Bronchi virology, Lung virology, SARS-CoV-2 growth & development, Viral Tropism, Virus Replication
- Abstract
The emergence of SARS-CoV-2 variants of concern with progressively increased transmissibility between humans is a threat to global public health. The Omicron variant of SARS-CoV-2 also evades immunity from natural infection or vaccines
1 , but it is unclear whether its exceptional transmissibility is due to immune evasion or intrinsic virological properties. Here we compared the replication competence and cellular tropism of the wild-type virus and the D614G, Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2) and Omicron (B.1.1.529) variants in ex vivo explant cultures of human bronchi and lungs. We also evaluated the dependence on TMPRSS2 and cathepsins for infection. We show that Omicron replicates faster than all other SARS-CoV-2 variants studied in the bronchi but less efficiently in the lung parenchyma. All variants of concern have similar cellular tropism compared to the wild type. Omicron is more dependent on cathepsins than the other variants of concern tested, suggesting that the Omicron variant enters cells through a different route compared with the other variants. The lower replication competence of Omicron in the human lungs may explain the reduced severity of Omicron that is now being reported in epidemiological studies, although determinants of severity are multifactorial. These findings provide important biological correlates to previous epidemiological observations., (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2022
- Full Text
- View/download PDF